Potential Deleterious Effects of Vasopressin in Chronic Kidney Disease and Particularly Autosomal Dominant Polycystic Kidney Disease
Authors:
- W.E. BoertienWBW.E. Boertien
- R. ZietseRZR. Zietse
- R.T. GansevoortRGR.T. Gansevoort
Open Access
- 31 May 2011
- journal article
- review article
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 34 (4) , 235-244
Abstract
The antidiuretic hormone vasopressin is crucial for regulating free water clearance in normal physiology. However, it has also been hypothesized that vasopressin has deleterious effects on the kidney. Vasopressin is elevated in animals and patients with chronic kidney disease. Suppression of vasopressin activity reduces proteinuria, renal hypertrophy, glomerulosclerosis and tubulointerstitial fibrosis in animal models. The potential detrimental influence of vasopressin is probably mediated by its effects on mesangial cell proliferation, renin secretion, renal hemodynamics, and blood pressure. In this review, we discuss the increasing body of evidence pointing towards the contribution of vasopressin to chronic kidney disease progression in general and to autosomal dominant polycystic kidney disease in particular. These data allude to the possibility that interventions directed at lowering vasopressin activity, for example by the administration of vasopressin receptor antagonists or by drinking more water, may be beneficial in chronic kidney disease.Keywords
This publication has 45 references indexed in Scilit:
- Copeptin, a Surrogate Marker of Vasopressin, Is Associated with Disease Severity in Autosomal Dominant Polycystic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2011
- Vasopressin induces phosphorylation of the thiazide-sensitive sodium chloride cotransporter in the distal convoluted tubuleKidney International, 2010
- Plasma Copeptin and the Risk of Diabetes MellitusCirculation, 2010
- Vasopressin in chronic kidney disease: an elephant in the room?Kidney International, 2009
- Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic ratsClinical and Experimental Nephrology, 2009
- Endothelial Markers May Link Kidney Function to Cardiovascular Events in Type 2 DiabetesDiabetes Care, 2009
- Sodium Excretion in Response to Vasopressin and Selective Vasopressin Receptor AntagonistsJournal of the American Society of Nephrology, 2008
- Copeptin: clinical use of a new biomarkerTrends in Endocrinology & Metabolism, 2008
- Vasopressin V2receptor expression along rat, mouse, and human renal epithelia with focus on TALAmerican Journal of Physiology-Renal Physiology, 2007
- Plasma and platelet vasopressin in essential hypertension and congestive heart failure.Hypertension, 1983